LEADER 05010nam 2201321z- 450 001 9910557689603321 005 20231214133228.0 035 $a(CKB)5400000000044635 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69089 035 $a(EXLCZ)995400000000044635 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFeature Paper in Antibiotics for 2019 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (282 p.) 311 $a3-03943-122-6 311 $a3-03943-123-4 330 $aThere has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous ?O?Neill Report? (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single ?whole of health? co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around ?forever? will come to our rescue?bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages. 606 $aMedicine$2bicssc 610 $aAntimicrobial resistance 610 $aantibiotics 610 $aantimicrobial stewardship 610 $ainappropriate prescribing 610 $adays of therapy 610 $aStart Smart then Focus 610 $apiperine 610 $apiperlongumine 610 $aantibacterial 610 $aantifungal 610 $asynergy 610 $anon-target feed 610 $aflorfenicol 610 $athiamfenicol 610 $achloramfenicol 610 $aHPLC-MS/MS 610 $avalidation 610 $aswine 610 $aout-of-hours care 610 $aprimary care 610 $aquality of care 610 $aquality indicators 610 $apractitioners cooperative 610 $aantibiotic stewardship 610 $afluoroquinolones 610 $aguidelines 610 $aurinary tract infections 610 $aquality improvement 610 $ageneral practitioners 610 $aguideline 610 $ahealth inequalities 610 $ahealth equity assessment tool 610 $apublic health 610 $aEnterobacteriaceae 610 $acarbapenem-resistant 610 $aCRE 610 $aantibiotic resistance 610 $aantimicrobials 610 $abacteriophages 610 $abiofilms 610 $anovel antimicrobials 610 $aAntibiotics 610 $aresistance 610 $abroad-spectrum agents 610 $ahospital epidemiology 610 $aantibiotic utilization 610 $ainfection control 610 $ainfection prevention 610 $aPseudomonas aeruginosa 610 $aAcinetobacter baumannii 610 $aextended-spectrum beta-lactamases 610 $acarbapenem-resistant Enterobacteriaceae 610 $amethicillin-resistant Staphylococcus aureus 610 $aclinical trials 610 $ainfectious disease 610 $aphage therapy 610 $asilver complexes 610 $acamphorimine 610 $aanti-Candida activity 610 $aantifungals 610 $aantibacterials 610 $aefflux inhibitors 610 $aefflux pumps 610 $aerm(41) 610 $amutations 610 $amycobacteria 610 $averapamil 610 $aactinomycetes 610 $abioactivity 610 $apolyketides 610 $apolyketide synthases 610 $abiosynthesis 610 $aantimicrobial resistance 610 $aeconomic evaluation 610 $acost-utility analysis 610 $acost-effectiveness analysis 610 $apolicy analysis 610 $aOne Health 610 $aSingapore 610 $aantibiotic prescribing 610 $aimplementation 610 $abehavior change 610 $astakeholder consultation 615 7$aMedicine 700 $aLipman$b Jeffrey$4edt$01318428 702 $aLipman$b Jeffrey$4oth 906 $aBOOK 912 $a9910557689603321 996 $aFeature Paper in Antibiotics for 2019$93033231 997 $aUNINA